Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis
Author(s) -
Angelo Ferrante,
Anna Giardina,
Francesco Ciccia,
Gaspare Parrinello,
Giuseppe Licata,
Giuseppe Avellone,
Emiliano Giardina,
R Impastato,
G Triolo
Publication year - 2009
Publication title -
rheumatology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.806
H-Index - 74
eISSN - 1437-160X
pISSN - 0172-8172
DOI - 10.1007/s00296-009-0935-2
Subject(s) - medicine , methotrexate , rheumatoid arthritis , rheumatology , intima media thickness , tumor necrosis factor alpha , necrosis , surgery , gastroenterology , carotid arteries
The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant variation of ca-IMT was observed after 2 years in MTX-treated patients. Our study indicates that anti-TNF blocking agents, but not methotrexate, are capable of reducing IMT of carotid arteries in female RA patients in a 2-year follow-up.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom